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Abstract--Resveratrol, a natural compound endowed with multiple health-promoting effects has received 
much attention given its potential for the treatment of cardiovascular, inflammatory, neurodegenerative, 
metabolic and age-related diseases. However, the translational potential of resveratrol has been limited by 
its specificity, poor bioavailability and uncertain toxicity. In recent years, there has been an accumulation 
of evidence demonstrating that resveratrol modulates sphingolipid metabolism.  Moreover, resveratrol 
forms higher order oligomers that exhibit better selectivity and potency in modulating sphingolipid 
metabolism. This review evaluates the evidence supporting the modulation of sphingolipid metabolism and 
signaling as a mechanism of action underlying the therapeutic efficacy of resveratrol and oligomers in 
diseases, such as cancer. 
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1. Introduction 
)LUVW LVRODWHG LQ WKH V UHVYHUDWURO ƍ-trihydroxy-trans-stilbene) received little attention until 50 
years later when it was found to be a major ingredient in red wine and identified as a chemo-preventive 
agent (Baur and Sinclair 2006). It is no surprise that resveratrol has been dubbed the ³HOL[LURIHWHUQDO\RXWK´
in view of its beneficial effects in preventing or slowing the progression of many human diseases by 
mediating cardiovascular protection, modulating lipoprotein metabolism and extending lifespan with its 
anti-inflammatory, anti-oxidant, anti-cancer and anti-aging properties (Orallo 2008). Despite advances in 
the field with evidence obtained from preclinical models, it is hard to comprehend how a simple molecule 
like resveratrol could act on a vast number of targets. Recently, several phytochemicals including 
resveratrol have been shown to inhibit membrane proteins non-specifically through perturbation of the lipid 
bilayer (Ingolfsson et al. 2014). In addition, many distal targets of resveratrol have been found but few 
studies have identified direct binding partners of resveratrol.  
Using techniques such as X-ray crystallography, computer simulation and modeling, affinity 
chromatography, nuclear magnetic resonance studies, biochemical and biophysical analyses, several bona 
fide resveratrol binding targets have been characterized. These include sirtuin 1 (Sinclair and Guarente 
2014), HVWURJHQUHFHSWRUĮ(Nwachukwu et al. 2014), cAMP phosphodiesterases (Park et al. 2012), cardiac 
protein troponin C (Pineda-Sanabria et al. 2011), leukotriene A4 hydrolase (Oi et al. 2010),  
cyclooxygenase 1 and 2 (Szewczuk et al. 2004; Zykova et al. 2008), F1-ATPase (Gledhill et al. 2007) and 
quinine reductase 2 (Buryanovskyy et al. 2004). These biological targets link resveratrol to its pleiotropic 
effects such as lifespan extension, cardio-protection and chemoprevention. Another possibility for poly-
pharmacology might be that, like a µbutterfly effect¶, resveratrol perturbs the activity of certain signaling 
molecules that regulate diverse functions in cellular homeostasis. Indeed, resveratrol is known to act on 
critical nodes in various signaling pathways including the phosphatidylinositol 3-kinase/Akt/mammalian 
target of rapamycin (PI3K/Akt/mTOR) pathway (Widlund et al. 2013), estrogen signaling (Mobasheri and 
Shakibaei 2013; Signorelli and Ghidoni 2005),  AMP-activated protein kinase/sirtuin 1/peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (AMPK/SIRT1/PGC-Į pathway (Baur et al. 
2012; Canto and Auwerx 2012) and stress-induced NF-ț% signaling (Gupta et al. 2014; Wu et al. 2013).  
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Sphingolipids constitute one of the major classes of lipids in cells with diverse effects in regulating cellular 
processes, such as proliferation, survival, migration, differentiation and angiogenesis. Accumulating 
evidence suggests that some of the pharmacological activities of resveratrol are, in part, mediated through 
changes in sphingolipid metabolism. Moreover, resveratrol forms many bioactive oligomers, although these 
are less well characterized. This review aims to update the reader about the biological activity of resveratrol 
and to provide a current understanding of its effects on sphingolipid metabolism and signaling. Evidence 
will be presented for enhanced selectivity or potency of resveratrol oligomers. We will also discuss the 
therapeutic roles of resveratrol with respect to sphingolipid biology in various disease states.  
1.1 Origin and activity of resveratrol oligomers 
Resveratrol, produced in plants, belongs to a class of secondary metabolites known as stilbenoids that 
consist of two phenol rings linked together with an ethylene bridge (Fig. 1). The dietary source and activity 
of resveratrol have been extensively studied and reviewed (Baur and Sinclair 2006; Burns et al. 2002; 
Shukla and Singh 2011). Nevertheless, resveratrol can oligomerize to form oligostilbenoids in diverse plant 
families such as Dipterocarpaceae, Vitaceae, Leguminosae, Cyperaceae, and Gnetaceae (Sotheeswaran and 
Pasupathy 1993). Here we focus on resveratrol and its oligomers produced by plants in the 
Dipterocarpaceae, Hopea genus. Dipterocarpaceae is a well-known family of rainforest trees, which consist 
of approximately 500 species with greater than 100 species in the Hopea genus distributed mainly in 
tropical countries (Dayanandan et al. 1999). Selected resveratrol oligomers are presented in Fig. 1 to show 
the complexity achieved by natural oligomerization. A common biosynthetic route of these resveratrol 
oligomers has been proposed (Sotheeswaran and Pasupathy 1993) but their isolation from natural products 
has been a daunting task and it is not until recently that total synthesis has become feasible (Snyder et al. 
2011).  
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Figure 1. Representative structures of resveratrol and its oligomers isolated from Hopea 
dryobalanoides. Relative stereochemistry of each molecule is indicated. 
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Resveratrol tetramers 
Hopeaphenol, a resveratrol tetramer, was one of the first compounds isolated from Hopea odorata and its 
structure confirmed by X-ray crystallography (Coggon et al. 1965; Coggon et al. 1966). Later, this 
compound was purified from other species in the same genus including Hopea dryobalanoides, Hopea 
malibato and Hopea parviflora (Dai et al. 1998; Sahidin et al. 2005; Tanaka et al. 2000). Interestingly, 
hopeaphenol has also been found in other plant genera including Neobalanocarpus heimii, Dipterocarpus 
hasseltii and Vitis vinifera (Muhtadi et al. 2006; Weber et al. 2001; Yan et al. 2001) suggesting its common 
existence as an important secondary metabolite. Hopeaphenol has strong growth inhibitory action against 
several cancer cells, such as human epidermoid nasopharynx carcinoma (KB), lung cancer carcinoma 
(A549), breast cancer (MCF-7) and murine leukaemia cells (P-388) (Muhtadi et al. 2006; Ohyama et al. 
1999). Hopeaphenol also exhibits moderate anti-microbial activity against Mycobacterium smegmatis and 
methicillin-resistant Staphylococcus aureus (Zgoda-Pols et al. 2002). More recently, hopeaphenol has been 
found to block the type III secretion system essential for pathogenicity of gram negative bacteria, 
suggesting a selective inhibition of bacterial virulence (Zetterstrom et al. 2013). Taken together, 
hopeaphenol is one of the most active compounds produced by tropical trees. However, its mechanisms of 
action and direct protein targets remain to be elucidated. Vaticanol B is another resveratrol tetramer 
isolated from Hopea dryobalanoides and has been shown to moderately inhibit P-388 cell growth (Muhtadi 
et al. 2006; Sahidin et al. 2005). Vaticanol B has weaker growth inhibitory action compared with 
hopeaphenol,  but exhibits anti-inflammatory effects that protect cells from ER-stress by inhibiting the 
activation of the unfolded protein response (UPR) genes (Tabata et al. 2007). Vaticanol C (an isomer of 
vaticanol B) induces apoptosis in various human cancer cell lines and a mouse mammary tumor model by 
perturbing mitochondrial membrane potential, activating pro-apoptotic proteins, such as caspases and Bad, 
down-regulating pro-survival signaling molecules, such as BCL2 and inhibiting ERK and Akt signaling 
pathways (Ito et al. 2002; Ito et al. 2003; Ohguchi et al. 2005; Shibata et al. 2007). Further investigations 
are needed to assess the pharmacokinetics of vaticanol C and potential toxicity in view of its therapeutic 
potential as an anti-cancer agent. 
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Resveratrol trimers 
Į-viniferin is a resveratrol trimer isolated from grapes of the common grape vine (Vitis vinifera) and 
exhibits anti-fungal activity (Langcake and Pryce 1977a). ,QWHUHVWLQJO\UHVYHUDWUROİ-viniferin (dimer) and 
Į-viniferin (trimer) have been produced successively in a time-dependent manner under UV irradiation, 
indicating that the biosynthetic precursor is indeed, the resveratrol monomer (Langcake and Pryce 1977b). 
6LPLODUWRRWKHUUHVYHUDWUROROLJRPHUVĮ-viniferin inhibits cancer cell growth but fails to induce apoptosis 
of colon cancer cells (Gonzalez-Sarrias et al. 2011). Į-viniferin suppresses interferon-Ȗ-induced 
inflammation in mouse macrophages by down-regulating signal transducer and activators of transcription 1 
(STAT1)-inducible inflammatory proteins, such as inducible NO synthase (iNOS), interferon-Ȗ-inducible 
protein-10 (IP10) and monokine-induced by interferon-Ȗ (MIG) (Chung et al. 2010). Į-viniferin also 
reduces both early and late stages of LPS-induced inflammation in BV2 microglial cells through inhibition 
of PI3K/Akt-dependent NF-ț% activation, reduced formation of pro-inflammatory molecules such as nitric 
oxide and prostaglandin E2 and suppression of nuclear factor erythroid 2±related factor 2 (Nrf2)- mediated 
haem oxygenase-1 expression (Dilshara et al. 2014). In vitro enzyme assays shows WKDW Į-viniferin has 
favorable anti-cholinesterase activity that might be useful for the treatment of Alzheimer¶V disease (Pinho 
et al. 2013; Sung et al. 2002; Yan et al. 2012). Į-viniferin also exhibits activity against serotonin (5-HT6) 
receptor (Kim et al. 2010), DNA topoisomerase II (Yamada et al. 2006), multidrug resistance-associated 
protein 1 (MRP1/ABCC1) (Bobrowska-Hagerstrand et al. 2006), COX-1 (Lee et al. 1998), COX-2 (Chung 
et al. 2003) and protein kinase C (Kulanthaivel et al. 1995; Xu et al. 1994). Together, these studies reveal 
an interesting insight into the mechanism of action of Į-viniferin. This resveratrol trimer not only interacts 
with a large number of targets (estimated to be as diverse as resveratrol) but also has improved potency and 
may selectively access other biological targets with an ³RSWLPDO´VWructure (see section 1.2 for discussion 
on resveratrol oligomerization). However, compared to the number of studies dedicated to resveratrol, 
fewer investigations have focused on Į-viniferin. Future studies using animal models are needed to 
examine the physiological and therapeutic relevance of these targets since all studies cited above have only 
DVVHVVHGĮ-viniferin in vitro.  
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Resveratrol dimers 
Parviflorol, diptoindonesin D, balanocarpol, heimiol A and hopeafuran are examples of resveratrol dimers 
isolated from Hopea dryobalanoides (Sahidin et al. 2005). Parviflorol was first isolated from Hopea 
parviflora as a yellow solid and has moderate growth-inhibitory activity in cancer (Sahidin et al. 2005; 
Tanaka et al. 2000). Diptoindonesin D was subsequently isolated as a derivative (8-ketone) of parviflorol. 
Heimiol A was isolated as a light brown solid from Neobalanocarpus heimii (Weber et al. 2001). In fact, 
parviflorol and diptoindonesin D are modified dimers of resveratrol whereas balanocarpol and hopeafuran 
are derivatives of ampelopsin A (Fig. 1). Little information is available on the activities of these dimers. 
Notably, malibatol A and B isolated from Hopea malibato were found to be active against HIV in cultured 
human lymphoblastoid cells (Dai et al. 1998). Although balanocarpol shares similar structure with 
malibatol A and B, it has only modest activity against HIV. Kinetic inhibition studies establish that 
balanocarpol is a mixed competitive inhibitor (with sphingosine) of sphingosine kinase 1 (SK1) (Lim et al. 
2012a). Despite successful isolation of resveratrol oligomers, further study has been hampered by low yield 
of these compounds and limited availability through total synthesis (Snyder et al. 2011). Conversely, 
resveratrol monomer is widely available and easily accessible; hence, is also extensively studied. 
Resveratrol monomer 
Several comprehensive reviews have been published concerning the in vitro and in vivo activities of 
resveratrol (Baur and Sinclair 2006; Signorelli and Ghidoni 2005; Widlund et al. 2013) . Therefore, a brief 
overview of its activity will be discussed here in relation to recent updates. Found abundantly in grapes and 
various dietary sources resveratrol has been isolated from over 70 plant species (Jang et al. 1997). 
Resveratrol is active against various human cancers as shown in cultured tumor cell and animal cancer 
models (Buryanovskyy et al. 2004). Anti-oxidant and anti-inflammatory effects were first proposed as the 
mechanisms for the anti-cancer and chemoprevention properties of resveratrol, which has phenol rings 
(strong scavengers of reactive oxygen species) and is able to inhibit COX-1 and COX-2 activities (Jang et 
al. 1997; Leonard et al. 2003; Subbaramaiah et al. 1998).  
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The anti-cancer activity of resveratrol has also been linked to perturbation of sphingolipid metabolism. In 
particular, resveratrol stimulates ceramide synthesis to induce apoptosis in breast cancer cells (Scarlatti et al. 
2003). Resveratrol might also reduce the production of the pro-survival sphingolipid, sphingosine 1-
phosphate (S1P).  For example, resveratrol inhibits the activation of SK1 by phospholipase D and reduces 
SK1 expression to suppress pro-survival signaling in prostate cancer cells (Brizuela et al. 2010). Using an 
in vitro enzyme activity assay, SK1 has been found to be directly inhibited by resveratrol and balanocarpol 
(Lim et al. 2012a). Moreover, balanocarpol is two-fold more potent than resveratrol, suggesting that 
dimerization increases binding affinity for SK1 (see section 1.2 and Fig. 2). In addition to catalytic 
inhibition, both resveratrol and balanocarpol also down-regulate SK1 expression (Lim et al. 2012a). 
Therefore, resveratrol suppresses cell growth and induces apoptosis possibly by modulating the balance of 
ceramide and S1P in cancer cells. 
Intense interests on resveratrol is due to its famous link with WKH³)UHQFKSDUDGR[´ where Mediterranean 
residents who consume red wine apparently have lower incidence of cardiovascular-related death, 
suggesting that resveratrol provides cardioprotection (Fremont 2000). However, a recent study that 
followed 783 elderly individuals who regularly consumed diets rich in resveratrol has found no significant 
association between any health benefits and total urinary resveratrol metabolite, casting doubts on its 
health-promoting effects (Semba et al. 2014). It is important to note that red wine (Guebailia et al. 2006) 
and other diets (Baechler et al. 2014; Barthomeuf et al. 2006) also contain significant amount of resveratrol 
oligomers that might be responsible for some of the beneficial health effects. 
Notably, several plant polyphenols having similar structural moieties (e.g. piceatannol and resveratrol) 
were found to modulate life span and aging by activating sirtuin 1 (SIRT 1) (Howitz et al. 2003). The life 
span of yeast (Saccharomyces cerevisiae) was extended by 70% at low micromolar concentrations of 
resveratrol and attributed to activation of sirtuins that stabilize ribosomal DNA repeats rather than its anti-
oxidant activity (Howitz et al. 2003). Subsequently, resveratrol has been shown to have similar effects as 
calorie restriction in prolonging the lives of roundworms, fish, flies, bees and mice (fed on a high-fat diet), 
indicating an evolutionary conserved mechanism of SIRT1 in regulation of health and lifespan (Baur et al. 
2012; Sinclair and Guarente 2014). However, resveratrol-induced activation of SIRT1 and its role in 
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prolonging lifespan is controversial with divergent views on whether this is a direct effect. In vitro assays 
measuring the activation of SIRT1 by resveratrol has been found to be dependent on fluorogenic substrates, 
raising doubts on the robustness of the assay (Borra et al. 2005; Kaeberlein et al. 2005). A recent study by 
Park and colleagues also supports an indirect effect of resveratrol via inhibition of cAMP 
phosphodiesterases leading to activation of the AMPK/SIRT1 signaling pathway (Park et al. 2012). Despite 
these findings, resveratrol has been shown to bind to and activate SIRT1 directly via an allosteric 
mechanism (Hubbard et al. 2013), indicating that the anti-aging effect of resveratrol might be SIRT1-
dependent (Sinclair and Guarente 2014). A subset of low molecular weight chemicals with related stilbene 
scaffolds can also activate SIRT1 (Howitz et al. 2003). Since resveratrol oligomers might have similar 
targets, it will be of interest to investigate whether resveratrol oligomers can activate SIRT1 and mimic life-
extending and health-promoting effects of calorie restriction. 
1.2 Resveratrol oligomerization  
Why would nature produce structurally diverse resveratrol oligomers? There are several possible 
explanations when looking at the evolution of conserved biosynthetic pathways. Indeed, two models have 
been proposed for the evolution of structurally-related natural compounds: target-based and diversity-based 
models (Fischbach and Clardy 2007). The first model consists of secondary metabolites that show high 
affinity for their respective biological targets and these molecules have evolved to improve host survival. 
For example, rapamycin (a polyketide) is an immunosuppressant that specifically inhibits FK-binding 
protein (FKBP-12) and mammalian target of rapamycin (mTOR) by forming a FKBP-12-rapamycin-mTOR 
complex (Choi et al. 1996). This elegant work demonstrates that rapamycin functions as a ¶molecular glue¶ 
that simultaneously blocks downstream signaling of two different proteins. The second model posits that 
evolution favors the survival of organisms that can maximize the diversity of their secondary metabolites. 
For example, terpenes consist of a large group of organic compounds, all derived from a simple building 
block, the isoprene (C5H8). At least 136 distinct gibberellin-family diterpenes are found in nature but only a 
few of them have potent biological effects; most are regarded as side products that lack activity (Fischbach 
and Clardy 2007). Therefore, certain secondary metabolites are synthesized in a diversity-oriented 
approach to maximize diversity and minimize metabolic cost by utilizing a common building block. In 
 12 
 
common with terpenes, resveratrol oligomerization is regarded as a diversity-oriented approach and 
evidence will be provided in the following to support this possibility.  
Resveratrol oligomerization possibly arises through the need for improved potency and selectivity. Qiao 
and colleagues screened 31 resveratrol oligomers and found that several trimers and one tetramer are more 
effective than the monomers or dimers in suppressing growth of several human cancer cell lines (Table 1). 
These workers investigated the anti-tumor efficacy of pauciflorol B (trimer) in a murine tumor model and 
established p53-dependent apoptosis and cell senescence as the mechanisms of action (Qiao et al. 2013). 
Similarly, the rank of potency for growth inhibition in P-388 murine cancer cells is hopeaphenol (tetramer) > 
Į-viniferin (trimer) > balanocarpol (dimer) (Sahidin et al. 2005) ,Q DGGLWLRQ İ-viniferin (dimer) and 
miyabenol C (trimer) induced apoptosis in human myeloma U266 cells at lower concentrations than 
resveratrol (Barjot et al. 2007). Vaticanol C (tetramer) is also 4-7 fold more potent than resveratrol in 
killing SW480 and HL60 colon cancer cells (Ito et al. 2003). The anti-inflammatory activity is also 
increased with oligomerization since, vaticanol B (tetramer) is more active than resveratrol monomer and 
dimer (Tabata et al. 2007). Taken together, oligomerization improves the anti-cancer properties of 
resveratrol in terms of growth suppression and apoptosis. 
Other cellular targets such as DNA topoisomerase II have been found to be more effectively inhibited by 
resveratrol oligomers (e.g. hopeaphenol) compared with the resveratrol monomer (Baechler et al. 2014). 
Interestingly, molecular size does not seem to be a constraint on the potency of higher order resveratrol 
oligomers since resveratrol hexamer still retains comparable activity compared with other tetramers against 
DNA topoisomerase II (Yamada et al. 2006). In the latter study, oligomers with higher repeating resveratrol 
units are also more active than smaller molecules (Table 1). In contrast, resveratrol is the most potent 
compound in inhibiting tyrosinase (an oxidase mediating the production of melanin) whereas modification 
of resveratrol by glucosidation (e.g. piceid), reduction (e.g. dihydroresveratrol) and oligomerization (e.g. Į-
viniferin) greatly reduces or abolishes activity against tyrosinase (Ohguchi et al. 2003). Į-viniferin (trimer) 
inhibits cholinesterase (implicated in Alzheimer¶V disease) whereas resveratrol is not active at 
concentrations up to 500µM (Pinho et al. 2013). Moreover, Į-viniferin (trimer) is the most potent inhibitor 
of cholinesterase compared with the tetramer, kobophenol A (Sung et al. 2002). ,QDGGLWLRQĮ-viniferin is 
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also 3-4-fold more potent than resveratrol at reducing prostaglandin H2 activity (Lee et al. 1998). Į-
viniferin is also the most potent compound in blocking MRP1/ABCC1 activity whereas resveratrol is 
inactive (Bobrowska-Hagerstrand et al. 2006), indicating that some enzymes and proteins have strict steric 
and conformational requirements for resveratrol oligomers.  
Another target of resveratrol oligomers is SK1, which catalyzes the phosphorylation of sphingosine to 
produce the bioactive lipid, S1P. S1P maintains cell survival and growth (Pyne and Pyne 2000) and is also 
involved in plant signaling (e.g. transpiration and seed germination) (Worrall et al. 2008). We found that 
balanocarpol (dimer) is more potent in inhibiting SK1 with an inhibition constant (Ki) of 90 ±ȝ0 
compared with that for resveratrol of 160 ± ȝ0  7KHVH ILQGLQJV VXJJHVW WKDW dimerization increases 
potency against SK1 (Lim et al. 2012a). The molecular interactions of resveratrol and balanocarpol with 
SK1; the crystal structure having been recently resolved (Wang et al. 2013) have now been modeled by us 
(Fig. 2). The predicted binding mode of resveratrol shows that its hydroxyl groups forms hydrogen bonds 
with the backbone carbonyl of L268 and L299 and one of the side chain oxygens of D178 (the 
deprotonating base enabling nucleophilic attack by sphingosine RQ WKHȖ-phosphate group of ATP) in the 
catalytic site of SK1. Due to increased size and number of hydroxyl groups (six in total), balanocarpol is 
modelled to bind to L268 and D178 but can form additional hydrogen bonds with the side chain oxygen of 
T196, the second carboxylate oxygen of D178 and the backbone carbonyl of A262. These modelling data 
can therefore provide an explanation for the increased potency of balanocarpol compared with resveratrol 
in inhibiting SK1 activity. 
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Figure 2. Binding modes obtained by docking resveratrol (left) and balanocarpol (right) in the 
sphingosine binding site of SK1 (PDB entry 3VZB). Chain A of the crystal structure of SK1 in complex 
with sphingosine was used to dock resveratrol and balanocarpol. The water molecule found to be tightly 
bound to the side chain ±OH of S168, the backbone ±NH of G342 and the secondary hydroxyl group of 
sphingosine is included in the modelling. Both compounds were docked using GOLD 5.2 for Windows 
(Cambridge Crystallographic Data Centre, Cambridge, UK), using default parameters and allowing the side 
chains of L259, L261, L263 and L302 to be freely flexible during the study. The flexibility of the side-
chains of these leucines was required to allow the sphingosine binding site of SK1 to accommodate the 
bulky balanocarpol.   
A distinct inhibitory profile has been documented for vitisin A and hopeaphenol, both of which are 
tetrameric forms of resveratrol. Unlike hopeahenol that consists of two repeating resveratrol dimers 
(DPSHORSVLQ% YLWLVLQ $ LV D FRPSOH[RIRQH İ-viniferin and one ampelopsin B. Opposing effects were 
observed for vitisin A (pro-apoptotic) and hopeaphenol (anti-apoptotic) on calcium-induced cytochrome C 
release and mitochondrial depolarization in cardiac myocytes (Seya et al. 2009). Peroxisome proliferator-
activated receptors (PPAR, nuclear receptors that act as transcription factors) are also activated by 
resveratrol and vaticanol C (tetramer) but QRW İ-viniferin (dimer) (Tsukamoto et al. 2010). In addition, 
vaticanol C binds PPARĮ and PPARȕį, yet resveratrol stimulates all isoforms of PPAR. Interestingly, 
vDWLFDQRO&RUİ-viniferin do not activate SIRT1 (Tsukamoto et al. 2010). Overall, these findings suggest 
that resveratrol oligomerization improves binding affinity (potency) and enhances target selectivity. 
Polyphenols produced by plants might be used by animals as a signaling cue to improve survival when 
confronted by environmental stress (Howitz and Sinclair 2008). This hypothesis (termed xenohormesis) 
was supported by observations that a wide range of natural compounds interact with different signaling 
pathways in animals. In fact, the similarity between many signaling molecules in plants and animals 
indicates that common biosynthetic pathways existed before the two kingdoms diverged (Kushiro et al. 
2003). A large amount of research over the past 20 years has shown that resveratrol not only serves specific 
roles in plant development and defense but can also target diverse signaling pathways in animals. The 
myriad biological functions of resveratrol might be explained by its simple, yet unique structure that has 
 15 
 
survived evolution. Thus, oligomerization provides a means to achieve better selectivity and potency to 
minimize metabolic cost. Further investigations of these compounds should provide impetus to fully 
develop the therapeutic potential of resveratrol. 
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Table 1. Relative efficacies of representative resveratrol oligomers for different signaling molecules 
and pathways 
Signaling pathway 
(Cell line or 
biological target) 
Monomer  
(IC50 µM) 
Dimer 
(IC50 µM) 
Trimer 
(IC50 µM) 
Tetramer 
(EC/IC50 
µM) 
References 
Apoptosis (SW480) resveratrol 
(22.1) 
İ-viniferin 
(>100) 
Į-viniferin 
(18.5) 
vaticanol C 
(3.6) 
hopeaphenol 
(28.6) 
 
(Ito et al. 
2003) 
Apoptosis (HL60) resveratrol 
(13.1) 
İ-viniferin 
(44.2) 
Į-viniferin 
(5.2) 
vaticanol C 
(3.0) 
hopeaphenol 
(21.3) 
 
Chromosome 
condensation (DNA 
topoisomerase II) 
resveratrol 
(262) 
balanocarpol 
(47) 
Į-viniferin 
(27) 
 
Į-viniferin 13-O-
ȕ-
glucopryranoside 
(4) 
hemsleyanol 
C (1) 
(Yamada et 
al. 2006) 
Cholinergic 
neurotransmission 
(Cholinesterase) 
resveratrol 
(>5) 
NA Į-viniferin 
(2) 
kobophenol 
A 
(115.8) 
(Pinho et al. 
2013; Sung 
et al. 2002) 
Drug resistance 
(MRP1) 
resveratrol 
(NE) 
İ-viniferin 
(8.9) 
Į-viniferin 
(0.8) 
NA (Bobrowska-
Hagerstrand 
et al. 2006) 
ER stress (F9 Herp-
null) 
resveratrol 
(NE) 
İ-viniferin 
(NE) 
NA vaticanol B 
(~5-10) 
(Tabata et al. 
2007) 
Gene transcription 
33$5Į 
resveratrol 
(5) 
İ-viniferin 
(NE) 
NA vaticanol C 
(2.5) 
(Tsukamoto 
et al. 2010) 
Growth inhibition 
(P-388) 
NA balanocarpol 
(33.6) 
Į-viniferin 
(25.8) 
hopeaphenol 
(5.7) 
(Sahidin et 
al. 2005) 
Growth inhibition 
(MCF7) 
 
Growth inhibition 
(MDA-MB-231) 
resveratrol 
(>70) 
 
resveratrol 
(>70) 
parviflorol 
(>30) 
 
parviflorol 
(>30) 
pauciflorol B 
(5.0) 
 
pauciflorol B 
(17.7) 
vaticaffinol 
(9.6) 
 
vaticaffinol 
(26.3) 
(Qiao et al. 
2013) 
Growth inhibition 
(MCF7) 
 
resveratrol 
(50) 
 
İ-viniferin 
(10) 
 
NA NA (Lim et al. 
2012a) 
Growth and 
survival (SK1) 
resveratrol 
(160)* 
İ-viniferin 
(90)* 
NA NA  
 
* values indicate inhibition constant (Ki); NA, Not Available; NE, Not Effective; ER, Endoplasmic 
Reticulum; MRP1, Multidrug Resistance-$VVRFLDWHG3URWHLQ33$5Į3HUR[LVRPH3UROLIHUDWRU-Activated 
5HFHSWRUĮ 
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1.3 Pharmacokinetics and toxicity 
One of the main obstacles in translating the beneficial effects of resveratrol to the clinic is its poor 
pharmacokinetic profile. Various studies have documented the bioavailability of resveratrol in human and 
animals. Resveratrol is quickly metabolized in the body to sulphate and glucuronide conjugates within 30 
minutes of intravenous administration; the half-lives of resveratrol and total resveratrol metabolite is 8-14 
minutes and approximately 9 hours respectively (Baur and Sinclair 2006). Notably, resveratrol sulphate is 
actively taken up by cells and provides a reservoir of intracellular resveratrol.  Peak plasma and local 
tissues concentration of resveratrol sulphate after oral dosing of 1g daily is 30 and 640 µM respectively 
(Patel et al. 2013). Resveratrol is delivered to cells as a sulphate conjugate that is further metabolized by 
the cells to regenerate resveratrol. Therefore, bioavailability of resveratrol and its route of 
administration/delivery system may not be a major concern. 
Toxicity is an issue that requires consideration. This is especially true for resveratrol, which has to be 
administered at high dosage to achieve clinical response including anti-cancer effects. However, resveratrol 
does not appear to have any detrimental effects in rats at 300mg/kg. Toxicity in man is less well studied or 
documented due to multiple challenges associated with human clinical trials (Smoliga et al. 2012). Very 
recently, resveratrol administered to non-human primates was found to exhibit several health benefits as 
observed from rodent studies. However, an abnormal developmental effect was found in fetal pancreas, 
arguing against the use of resveratrol in pregnant woman (Roberts et al. 2014). Resveratrol might also 
interact with other dietary supplements or drugs as it inhibits human cytochrome P450 (CYP) enzymes 
(Baur and Sinclair 2006).  Į-viniferin also inhibits 7 out of 9 human CYP isoforms that are involved in drug 
metabolism, indicating the potential for drug interactions (Sim et al. 2014). Consequently, toxicity and side 
effects of resveratrol and its oligomers should be thoroughly examined before they can be recommended 
for long-term use.  
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2. Sphingolipids  
Lipids (glycerolipids, sphingolipids and sterols) are ubiquitous biomolecules that are involved in the 
regulation of cellular homeostasis in health and disease. Bioactive sphingolipids play important roles in 
mammalian cell signaling (Hannun and Obeid 2008). The name of sphingolipids is derived from the 
P\VWLFDO ³VSKLQ[´ ZKLFK VXJJHVWV WKHLU HQLJPDWLF SURSHUWLHV For decades, sphingolipids have been 
considered as inert structural components of the cell membranes. Sphingolipids have come of age and have 
emerged as pleiotropic signaling molecules that regulate various cellular processes such as apoptosis 
(Hannun and Bell 1989).  Sphingolipids also stabilize lipid microdomains (or ³OLSLG UDIWs´) where cell 
signaling is compartmentalized and facilitated by the biophysical functions of sphingolipids (Futerman and 
Hannun 2004). Certain molecular species of ceramide induce apoptosis (Obeid et al. 1993) whereas 
sphingosine-1-phosphate (S1P) promotes cell proliferation (Olivera and Spiegel 1993), prevents apoptosis 
(Cuvillier et al. 1996) and functions as a ligand for five G-protein coupled receptors (named S1P1-5). 
Moreover, S1P signaling plays a major role in many human diseases including cancers (Pyne and Pyne 
2010) and immune disorders (Pyne and Pyne 2011). Furthermore, the sphingolipid pathway has been 
successfully targeted by Fingolimod (FTY720), the first FDA-approved drug modulating the S1P1 receptor 
and now licensed as Gilenya
® 
for the treatment of relapsing-remitting multiple sclerosis (Brinkmann et al. 
2010). In recent years, compounds such as RPC1063 and ponesimod (ACT-128800) that selectively target 
the S1P1 receptor have entered clinical trials for the treatment of autoimmune diseases including multiple 
sclerosis, psoriasis and ulcerative colitis. Moreover, the S1P specific monoclonal antibody, Sonepcizumab 
('S-one-P' cizumab) or LT1009 has been developed into two different formulations for clinical trials: (i) 
$621(3 for non-resectable and refractory kidney cancer DQG LL L621(3IRU age-related macular 
degeneration. These clinical evaluations highlight the therapeutic potential of modulating S1P signaling in 
chronic inflammatory diseases (Schwalm et al. 2014).  
2.1 Sphingolipid Metabolism 
There are a multitude of lipids with distinct structures that are present in cells (Futerman and Hannun 2004). 
This structural diversity and complexity is the result of the availability of diverse substrates for lipid-
metabolizing enzymes. With the advent of molecular cloning and biochemical analysis, the sphingolipid 
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metabolic pathways have been elucidated. The neutral building block of all sphingolipids is ceramide that 
is either formed by de novo synthesis at the endoplasmic reticulum (ER) or activation of sphingomyelinases 
which function in the so-called µsalvage pathway¶. In the ER, serine and pamitoyl coenzyme A is 
condensed by serine palmitoyl transferase (SPT) to form 3-ketosphinganine that is reduced to 
dihydrosphingosine followed by N-acylation to form dihydroceramide. In turn, dihydroceramide can be 
desaturated to form ceramide (Fig. 3). SPT has recently been shown to be negatively regulated by the Orm 
proteins that are encoded by the ORMDL genes in human (Breslow et al. 2010). Through genome wide 
association studies, ORMDL3 gene has been implicated as a significant risk factor for childhood asthma, 
primary biliary cirrhosis GLDEHWHV DQG &URKQ¶V GLVHDVH These findings suggest that disruption of 
sphingolipid homeostasis could play a role in pathogenesis of these inflammatory diseases (Breslow et al. 
2010). Sphingomyelinases catalyze the hydrolysis of sphingomyelin that is abundant in the cellular 
membrane to produce ceramide in the sphingosine salvage pathway. Sphingomyelinases are broadly 
categorized in neutral, acid or alkaline forms. Ionizing radiation activates acid sphingomyelinase to produce 
ceramide which promotes the induction of apoptosis (Haimovitz-Friedman et al. 1994), implicating a 
crucial role for this enzyme in mediating stress-induced apoptosis (Santana et al. 1996). Conversely, a cell 
permeable and non-competitive inhibitor of neutral sphingomyelinase (GW4869) blocks ceramide 
synthesis to rescue cell death in numerous cell types, such as cochlear hair cells (Chi et al. 2014), retinal 
pigment epithelial cells (Kucuksayan et al. 2014) and fibroblasts (Qin et al. 2012). At least four isoforms of 
neutral sphingomyelinase are expressed in mammalian cells, each with distinct biochemical properties, 
localizations and physiological roles (for a review, see Airola and Hannun 2013)). Alkaline 
sphingomyelinases are less well studied. These enzymes are expressed mainly in the intestines and could be 
implicated in various digestive tract diseases (Duan 2006). Together, these studies provide a strong 
rationale for therapeutic targeting of sphingomyelinases to modulate the level of ceramide in various 
diseases.  
Ceramide can be deacylated (removal of the fatty acid side chain) through a reaction catalyzed by 
ceramidase. Conversely, sphingosine can be acylated by ceramide synthase to produce ceramide. 
Phosphorylation of sphingosine is catalyzed by sphingosine kinase (two isoforms termed SK1 and SK2) to 
produce S1P, which can be recycled to sphingosine by lipid phosphate phosphatases or S1P specific 
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phosphatases. Alternatively, S1P is cleaved by S1P lyase to produce phosphoethanolamine and (E)-2-
hexadecenal and this represents the only exit point in the sphingolipid metabolic pathway (Fig. 3).  
 
Figure 3. Sphingolipid metabolism. Degradation of sphingomyelin or de novo synthesis produces 
ceramide that is the precursor of sphingosine, sphingomyelin and glycosphingolipids. Sphingosine is 
phosphorylated by sphingosine kinase to form sphingosine-1-phosphate (S1P) which can be recycled back 
to sphingosine by enzymes like S1P specific phosphatases. S1P is irreversibly cleaved by S1P lyase to exit 
the sphingolipid metabolic pathway. 
Understanding the metabolism of sphingolipids is essential to dissect the mechanisms of action for agents 
that perturb sphingolipid levels. In addition, these metabolic pathways are bi-directional and sphingolipid 
levels are tightly regulated in cells. For example, the apparent failure of a ceramide-inducing agent to 
promote apoptosis might be due to an active clearance of ceramide by ceramidase. Indeed, ceramidase 
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inhibitors might be usefully exploited to reduce ceramide clearance and hence potentiate ceramide-
dependent apoptosis (Canals et al. 2011). In diseased states, one or more of these metabolic pathways might 
be deregulated resulting in over-production of a metabolite; for example, by over-expression of the 
anabolic enzymes or down-regulation of the catabolic enzymes. Indeed, S1P levels are increased by 
elevated expression of SK1 in multiple human cancers (Pyne and Pyne 2010). In addition, down-regulation 
of alkaline sphingomyelinase has been observed in human colon and liver cancers leading to reduction of 
ceramide level and attenuation of apoptosis (Cheng et al. 2007; Duan 2005). Therefore, the interconversion 
of these sphingolipid metabolites must be considered when assessing the cellular phenotype upon gene 
knockdown or treatment with pharmacological therapeutic agents. 
2.2 Biological activity of sphingolipids    
The sphingolipid µrheostat¶ has been proposed as a model to explain the biological activity of ceramide, 
sphingosine and S1P in determining cell fate (Cuvillier et al. 1996). According to this concept, the balance 
of the ceramide, sphingosine and S1P levels defines whether cells undergo proliferation or apoptosis or 
senescence or differentiation The anti-apoptotic role of S1P has also been linked to the promotion of 
macroautophagy (simply termed as autophagy, a self-degradation process) (Lavieu et al. 2006). Autophagy 
maintains cellular homeostasis by regulating turnover of cellular components and plays important roles in 
determining cell fate (Green and Levine 2014). Autophagy can promote cell survival or cell death 
depending on which autophagy gene products are switched on (Codogno and Meijer 2005). Emerging 
evidence suggests that ceramide has a complex role in autophagy, promoting cell death in a context-
dependent manner (Jiang and Ogretmen 2014). Ceramide also has diverse cellular targets, such as protein 
phosphatase 2A, p38, JNK, PKC, survivin and other proteins that regulate cell cycle and apoptosis (Morad 
and Cabot 2013). On the other hand, sphingosine was initially found to inhibit protein kinase C, exert anti-
proliferative effects and exhibit cell-type specific functions (Hannun and Bell 1989). Sphingosine also 
regulates nuclear lipid signaling as it has been shown to bind the nuclear receptor, Steroidogenic Factor-1, 
that mediates steroid biosynthesis, and primase that regulates synthesis of RNA primers (Simbulan et al. 
1994; Urs et al. 2006). More recently, sphingosine has been found to activate Translesion DNA Polymerase 
to promote cell proliferation (Kamath-Loeb et al. 2014). Moreover, the cellular effects of sphingosine are 
 22 
 
cell-type and cell-context dependent. Notably, sphingosine can be converted to S1P by the action of SK1 or 
SK2 to stimulate cell proliferation. S1P functions both intracellularly (by binding to its target proteins) and 
extracellularly (through agonism of cell surface S1P-specific receptors). Moreover, the S1P signalling axis 
is implicated in many human diseases including inflammation and cancer (Dilshara et al. 2014; Kunkel et al. 
2013; Pyne and Pyne 2010), providing opportunities for development of SK1 or SK2 inhibitors and S1P 
receptor agonists or antagonists as therapeutic agents. 
2.3 S1P signaling 
S1P acts on extracellular receptors (S1P1-5) to regulate diverse cellular responses, such as cell proliferation, 
migration, differentiation and immune cell trafficking. Each receptor is preferentially coupled to a subset of 
G proteins that regulate various effectors. The effects of S1P receptor-mediated signaling depend on the 
relative expression of S1P receptor sub-types. S1P also acts intracellularly to promote epigenetic regulation, 
calcium mobilization, mitogenesis, inflammation and apoptosis suppression. Hence, to dissect the effects of 
S1P on cells, both extracellular and intracellular actions have to be considered.   
SK1 is activated in response to stimulation of many receptor types.  This involves SK1 translocation to the 
plasma membrane where S1P is formed. S1P may then be transported actively across the lipid bilayer (Kim 
et al. 2009) to act as an autocrine signal (³LQVLGH-RXW´ RU VHTXHQWLDO VLJQDOLQJ (Takabe et al. 2008)). By 
contrast, integrative signaling can enhance the co-migratory effect of extracellular S1P with other growth 
factors acting via S1P receptors and receptor tyrosine kinases (Waters et al. 2006).  
In the circulation, immune cell trafficking is regulated by a S1P gradient (high S1P concentration in blood 
and lymph, low S1P concentration in tissues) (Hla et al. 2008). The S1P transporter spinster homolog 2 
(Spns2) is responsible for S1P export from lymphatic endothelial cells, which mediates lymphocyte egress 
(Fukuhara et al. 2012). In the plasma, S1P is carried by apolipoprotein M in a complex with high-density 
lipoprotein (HDL) (Christoffersen et al. 2011). Apolipoprotein M not only functions as a vehicle to carry 
and deliver its S1P to different tissues but to also stimulate S1P synthesis in the liver (Liu et al. 2014) and 
to induce insulin secretion (Kurano et al. 2014).  
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Therapeutic targeting of S1P signaling has gained momentum with the recent resolution of the crystal 
structures of SK1 (Wang et al. 2013), S1P1 (Hanson et al. 2012) and S1P lyase (Bourquin et al. 2010). 
Molecular interactions between inhibitors and SK1 can now be modeled accurately to elucidate the 
structure-activity relationship of these inhibitors (Baek et al. 2013). The structure also provides an avenue 
for the study of potential allosteric modulators of SK1 (Lim et al. 2012b; Lim et al. 2001a; Liu et al. 2013). 
SK2, a larger protein than SK1 and with differing biochemical properties and distribution, is less well 
characterized. Nevertheless, SK2 appears to play a contributory role in cancer and inflammatory diseases as 
evidenced by the therapeutic effects observed with SK2 inhibitors in vitro and in preclinical disease models 
(Lim et al. 2011b, Neubauer and Pitson 2013). Therefore, solving the atomic structure of SK2 would 
accelerate the development of specific SK2 inhibitors and advance our understanding of the role of SK2 in 
various diseases. Similarly, the crystal structure of S1P1 provides mechanistic insights into how this 
receptor can be effectively targeted. Interestingly, the N-terminus and extracellular loops of the receptor 
blocks ligand access; S1P appears to slide horizontally in the transmembrane region to enter the binding 
pocket (Hanson et al. 2012). Since the only approved S1P1 modulator (FTY720) is not selective, 
development of specific S1P1 modulators is required to avoid effects on other S1P receptors.  Several orally 
active S1P lyase inhibitors are also in preclinical development, offering new approaches for the treatment 
of autoimmune diseases like multiple sclerosis and rheumatoid arthritis (Bagdanoff et al. 2010; Weiler et al. 
2014).        
Targeting S1P production or removal may affect receptor-mediated actions of S1P (i.e. extracellular) but 
also its intracellular actions.  For example, S1P has been found to play a role in the nucleus by binding to 
and inhibiting histone deacetylases (HDACs) (Hait et al. 2009). Phorbol ester can activate SK2 to increase 
S1P levels which bind to and inhibit HDAC1/2. This leads to up-regulation of cyclin-dependent kinase 
(CDK) inhibitor p21 and the proto-oncogene c-fos. This suggests that intracellular S1P is an important 
epigenetic regulator (Hait et al. 2009). In addition, S1P binds TRAF2 in the cytoplasm and increases 
TRAF2-dependent polyubiquitination of receptor interacting protein 1 (RIP1). RIP1 is a scaffold protein 
for IKK-dependent regulation of the NF-ț%  pathway that regulates pro-inflammatory responses (Alvarez 
et al. 2010). Intracellular S1P also regulates mitochondrial assembly and respiration by binding to a 
mitochondrial protein, prohibitin 2 and promoting respiratory complex IV assembly (Strub et al. 2011). In 
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addition, intracellular S1P can bind to DQG HQKDQFH ȕ-site APP cleaving enzyme-1 (BACE1) activity to 
increase ȕ-amyloid productLRQZKLFKFRQWULEXWHVWRWKHSDWKRJHQHVLVRI$O]KHLPHU¶VGLVHDVH (Takasugi et 
al. 2011). More recently, S1P binding to cellular inhibitor of apoptosis 2 (cIAP2) has been shown to trigger 
interferon-regulatory factor 1 (IRF1) polyubiquitination that is essential for IL1-dependent expression of 
CXCL10 and CCL5 chemokines (Harikumar et al. 2014). Recently, FTY720 phosphate (the SK2 
phosphorylated derivative of FTY720) was shown to inhibit HDACs in a fashion similar to S1P and to 
eliminate fear memories in mice, implicating a new role of S1P in memory formation (Hait et al. 2014). 
Together, these studies consolidate our understanding on S1P signaling in normal and pathological 
processes and reveal new therapeutic opportunities. 
3. Effects of resveratrol on sphingolipids in disease  
The prevalence of cancer, cardiovascular, neurodegenerative diseases and metabolic disorders increases 
with age. In this regard, the effects of resveratrol in slowing the progression of age-related diseases are well 
documented (Baur et al. 2012). Interestingly, sphingolipids, such as ceramide and dihydroceramide have 
been shown to modulate lifespan of yeast via autophagy and activation of AMPK signaling that is 
independent of sirtuin activation (Huang et al. 2014). Since resveratrol modulates sphingolipid levels, the 
beneficial effects of resveratrol such as anti-cancer, anti-inflammatory activities, cardio- and neuro-
protective properties might be tightly linked with changes in sphingolipid signaling. The following section 
provides evidence for the role of sphingolipids in mediating the activities of resveratrol in multiple human 
diseases.  
3.1 Cancer and Inflammation 
Resveratrol alters sphingolipid levels through multiple mechanisms. Firstly, resveratrol increases ceramide 
to induce apoptosis in colon, breast and prostate cancer cells. Similarly, synthetic resveratrol analogues 
with minor side-chain modifications induce ceramide-dependent apoptosis (Minutolo et al. 2005).  The 
effect of resveratrol is through increased de novo ceramide biosynthesis and is reversed by SPT inhibitors 
(Dolfini et al. 2007; Sala et al. 2003; Scarlatti et al. 2007; Scarlatti et al. 2003; Ulrich et al. 2007). However, 
ceramide levels increase 24-48 hours after resveratrol treatment (Scarlatti et al. 2003), which correlates 
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with the onset of apoptosis (Delmas et al. 2003; Dimanche-Boitrel et al. 2005), and suggesting de novo 
changes in the expression of enzymes involved in ceramide metabolism. The mechanisms by which 
resveratrol and ceramide induce apoptosis in ovarian cancer cells are partially overlapped and involve a 
COX-2-dependent pathway (Lin et al. 2013). Resveratrol also increases dihydroceramide levels by 
reducing the activity of dihydroceramide synthases in gastric cancer cells (Shin et al. 2012). There is also 
increasing evidence that resveratrol can induce autophagy by modulating sphingolipid levels in cancer cells. 
In this regard, resveratrol increases dihydroceramide levels and induces autophagy that is possibly linked 
with inhibition of growth of HCG-27 gastric cancer cells (Signorelli et al. 2009). In addition, resveratrol 
has been shown to induce autophagic cell death in human breast cancer (Scarlatti et al. 2008), colorectal 
cancer (Trincheri et al. 2008), ovarian cancer (Kueck et al. 2007) and chronic myelogenous leukemia cells 
(Puissant et al. 2010). Therefore, resveratrol induced changes in ceramide, dihydroceramide and S1P levels 
appear linked with inhibition of proliferation, stimulation of autophagy and induction of cancer cell death.   
Blockade of NF-ț% signaling is one of the early events observed with resveratrol treatment. For example, 
resveratrol abrogates TNF-induced activation of NF-ț% within 30 minutes of treatment (Ashikawa et al. 
2002; Manna et al. 2000). Moreover, pre-treatment of endothelial cells with SGE (a red grape skin 
polyphenolic extract, containing resveratrol oligomers) reduces the responsiveness of these cells to S1P-
induced migration, ERK1/2 activation and platelet-activating factor synthesis (Barthomeuf et al. 2006). NF-
ț%  is a proposed downstream effector of S1P (Alvarez et al. 2010).  Therefore, the effects of SGE in 
blocking S1P-dependent angiogenesis might lie upstream of NF-ț%.  Indeed, Issuree and colleagues (2009) 
showed that resveratrol inhibits SK1-induced inflammatory response triggered by C5a (a chemoattractant 
cytokine). Resveratrol also inhibits activation of phospholipase D (PLD) which is an upstream activator of 
SK1 (Issuree et al. 2009). Dietary polyphenols including resveratrol also down-regulate SK1 expression 
and activity in prostate cancer cells (Brizuela et al. 2010). These studies suggest that resveratrol inhibits the 
ERK/PLD pathway which is upstream of SK1 activation. However, direct inhibition of purified SK1 
activity by resveratrol has been observed and treatment of MCF-7 breast cancer cells with resveratrol 
induces down-regulation of SK1 expression (Lim et al. 2012a). The inhibition of SK1 activity by 
resveratrol is likely to disrupt the sphingolipid rheostat and to increase ceramide levels.  This might account 
for the ability of resveratrol to induce apoptosis of MCF-7 breast cancer cells (Lim et al. 2012a). Moreover, 
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balanocarpol and its isomer, ampelopsin A also inhibit SK1 activity and down-regulate SK1 expression, 
which induces apoptosis in MCF-7 breast cancer cells (Lim et al. 2012a). Interestingly, resveratrol up-
regulates ceramide synthases and down-regulates SK1 expression in myeloid leukemia cells (Cakir et al. 
2011). Resveratrol also reduces activity of SK1 in a rat model of ulcerative colitis and ablates severity of 
oxazolone-induced inflammation (Abdin 2013). Perturbation of the sphingolipid rheostat by resveratrol and 
oligomers might therefore be partly responsible for the anti-inflammatory and anti-cancer activities of these 
compounds. 
3.2 Cardiovascular disease 
Circulating S1P is bound to HDL (~ 55%), albumin (~ 35%) and LDL/VLDL (< 10%) and is derived from 
vascular endothelial and red blood cells in a range between 200-900 nM (Poti et al. 2014). At this 
concentration, S1P dissociates from its carrier proteins to exert cardiovascular and atheroprotective effects 
by binding to S1P receptors. Indeed, circulating S1P or activation of intracellular SK1 confers protection 
against myocardial infarction and acute ischemia/reperfusion injury (Karliner 2013). Even though the 
overall effect of S1P on the heart and vasculature appears protective after injury, several studies report 
conflicting results due to the pro-fibrotic, heart muscle thickening and vasoconstrictive properties of S1P 
(Waeber and Walther 2014). For instance, S1P3 is linked to bradycardia, an undesirable adverse effect of 
FTY720 phosphate (Means and Brown 2009). Therefore, compounds selectively targeting the S1P1 
receptor might be better suited for the treatment of myocardial infarction (Waeber and Walther 2014). The 
consensus is that further investigations employing larger animal models, selective pharmacological tools 
and more epidemiological studies are required to improve our understanding of the role of S1P and thereby 
enable development of new therapeutic agents for treatment of cardiovascular disease.  
Despite favorable outcomes observed for resveratrol and other polyphenolic compounds in many in vitro 
and in vivo models of cardiovascular disease, the evidence for cardioprotection is not unequivocal in 
humans based on clinical and epidemiological evidence (reviewed by (Khurana et al. 2013; Tome-Carneiro 
et al. 2013). For example, even though resveratrol appears beneficial against myocardial infarction in 
animal models, several recent large-scale analyses have argued against a protective effect of resveratrol in 
humans. In addition, the effect of resveratrol on lipoprotein metabolism is not significant in a meta-analysis 
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of seven randomized controlled trials (Sahebkar 2013). Similarly, Semba and colleagues did not find an 
association between resveratrol and any health benefits after following 783 individuals for 9 years (Semba 
et al. 2014). More long-term controlled trials will assess the use of resveratrol as a dietary supplement for 
prevention or as a drug for treatment of cardiovascular diseases.  
Since resveratrol and its oligomers modulate sphingolipid metabolism and increases pro-apoptotic ceramide 
levels, future studies should explore whether this effect is cell-type specific. For example, due to constant 
exposure to UV irradiation, keratinocytes have evolved a protective mechanism to convert ceramide to S1P 
by activating ceramidase and SK1 (Uchida 2014). Intriguingly, resveratrol increases ceramide levels (via 
activation of SPT) and S1P formation (by increasing SK1 mRNA expression), which leads to increased 
antimicrobial defense in human skin cells (Park et al. 2013). Therefore, possibly through this metabolic 
conversion of ceramide to S1P, resveratrol may have a protective role in some cell types. Low 
concentration of resveratrol (< ȝ0LQFUHDVHVVSKLQJRVLQH, ceramide and S1P levels in human skin cells 
but high concentration of resveratrol reduces cell viability (Park et al. 2013). This is consistent with the 
effect of resveratrol in cancer cells where high concentration (> ȝ0) of resveratrol induce apoptosis 
possibly involving inhibition of SK1 activity and down-regulation of SK1 expression (Lim et al. 2012a). 
Thus, the effects of resveratrol on SK activity and sphingolipid metabolism appear concentration dependent 
and this will define the effect of resveratrol on cellular outcome.  
Therefore, the use of resveratrol to modulate sphingolipid levels and signaling in cardiovascular disease 
requires careful consideration. Clearly, the ability of resveratrol to increase ceramide levels either by 
activating SPT or by inhibiting SK1 activity might dictate a pro-apoptotic effect which would be 
deleterious. Second, the multifaceted roles of S1P in the cardiovascular system make it difficult to harness 
the beneficial effects of reducing S1P levels while avoiding unwanted side-effects. For example, inhibiting 
SK1 activity with resveratrol might reduce cardioprotection afforded by S1P associated with HDL and 
S1P-dependent activation of pro-survival signaling such as PI3K/Akt and MAPK pathways.  However, S1P 
can reduce heart rate (S1P3) and constrict coronary arteries (S1P2) (Waeber and Walther 2014) and these 
effects would be potentially alleviated by inhibiting SK1 activity/expression with resveratrol. Indeed, 
resveratrol has been shown to be effective in ameliorating hypertension, ischemic heart disease and 
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cardiomyopathy in animal studies (Raj et al. 2014). A recent study has shown that resveratrol is effective in 
reducing arterial wall inflammation and stiffening (hallmarks of vascular aging) in rhesus monkeys fed 
with high fat diet, possibly through activation of the Nrf2 anti-oxidant pathway (Mattison et al. 2014). 
Resveratrol also exhibits anti-oxidant and anti-inflammatory properties due to modulation of other 
signaling pathways that might impact more significantly on cardioprotection than the modulation of S1P 
signaling. These include activation of AMPK, SIRT1 and NO signaling as well as inhibition of pro-
inflammatory cytokine signaling such as the NF-ț%  pathway (Raj et al. 2014). Therefore, further 
investigations are needed to examine the effect of resveratrol on sphingolipid levels in cardiovascular 
disease models. Investigation of WKH DFWLYLW\ RI UHVYHUDWURO ROLJRPHUV ZKLFK PLJKW EH ³ILQH-WXQHG´ Ln 
specificity of action is also worthwhile, particularly given their ability to inhibit SK1 activity. Long-term 
studies are also needed to assess the side effects and toxicity of these compounds. 
3.3 Neurodegenerative disease 
Altered sphingolipids metabolism is linked to multiple neurodegenerative diseases, such as Alzheimer's 
disease, Niemann Pick disease, amyotrophic lateral sclerosis, Parkinson and AIDS dementia (Mielke and 
Lyketsos 2010). The strongest evidence that modulation of sphingolipids by resveratrol might impact 
disease progression is in Alzheimer's disease. Alzheimer's disease is known to affect the elderly and is 
responsible for memory loss as a result of dementia. Central to the pathogenesis of Alzheimer's disease is 
BACE1 (also referred to as ȕ-secretase), which is an enzyme responsible for the formation of neurototoxic 
ȕ-amyloid and therefore, is a therapeutic target (Yan and Vassar 2014). S1P produced by SK2 has been 
found to be neurotoxic in S1P-lyase deficient mice (Hagen et al. 2011). SK2, located at the ER induces 
apoptosis by generating intracellular S1P or phosphorylating sphingoid-based substrates (Don et al. 2007; 
Maceyka et al. 2005). Moreover, knockdown of SK2 by siRNA or inhibition of SK2 activity with 
ABC294640 (a specific SK2 inhibitor, (French et al. 2010) UHGXFHV ȕ-amyloid production in N2a 
neuroblastoma cells, indicating that SK2-derived S1P activates BACE1 WR LQFUHDVH ȕ-amyloid level in 
mouse neurons (Takasugi et al. 2011). Therefore, inhibition of SK2 activity is predicted to have therapeutic 
YDOXH LQ UHGXFLQJ IRUPDWLRQ RI ȕ-amyloid.  Inhibition of SK1 activity by resveratrol is likely to be 
counteracted by the fact that ceramide (which is increased by resveratrol) which might accumulate also 
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increases ȕ-amyloid levels (by increasing BACE1 stability) (Puglielli et al. 2003) and induces oxidative 
stress in neurons (Cutler et al. 2004). Interestingly, other lipids (e.g. neutral glycosphingolipids, anionic 
glycerolipids and sterols) have also been shown to stimulate BACE1 activity in a reconstituted 
proteoliposome system (Kalvodova et al. 2005). Moreover, an increased ceramide/S1P ratio favors 
apoptosis that might result in further neurodegeneration. Indeed, ceramide levels are KLJK LQ$O]KHLPHU¶V
patient brain region that exhibit ȕ-amyloid accumulation (Cutler et al. 2004). In addition, serum ceramide is 
DOVR DVVRFLDWHG ZLWK LQFUHDVHG ULVN RI GHYHORSLQJ $O]KHLPHU¶V GLVHDVH LQ ZRPDQ (Mielke et al. 2012). 
Moreover, down-regulation of SK1 or up-regulation of S1P lyase (both of which would likely result in 
reduced S1P level) expression are found in $O]KHLPHU¶V patient brain tissue, suggesting that high 
ceramide/S1P ratio in the brain is neurotoxic (Ceccom et al. 2014; Couttas et al. 2014). Therefore, SK 
inhibitors (e.g. 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole, abbreviated as SKi) that inhibit both SK1 
and SK2 activity would appear counterproductive (Lim et al. 2011b; Loveridge et al. 2010; Mielke and 
Lyketsos 2010). In addition, SKi has been found to increase dihydroceramide levels, possibly by inhibiting 
dihydroceramide desaturase (Cingolani et al. 2014; Loveridge et al. 2010). Dihydroceramide might also be 
linked to autophagy and ER stress, which mediates G0/G1 cell cycle arrest and suppresses cell proliferation 
(Gagliostro et al. 2012). In addition, defects in autophagy-related pathways are implicated in 
neurodegeneration (Nixon 2013). Substantial evidence has now demonstrated that sphingolipids regulate 
both autophagy and apoptotic pathways to determine cell survival (Li et al. 2014).  
In Alzheimer's disease, resveratrol ameliorates various pathological features associated with ȕ-amyloid and 
Tau protein misfolding, inflammation, cell metabolism, telomere shortening, mitochondria dysfunction and 
oxidative stress (Granzotto and Zatta 2014; Vingtdeux et al. 2008). A beneficial effect has been 
demonstrated lately for resveratrol supplementation in elderly patients who exhibit better memory 
performance associated with improved glucose metabolism and hippocampal functional connectivity 
(Izeddin 2014). Other polyphenols have been shown to penetrate the brain and exhibit anti-amyloidogenic 
activity that improves cognitive function in a mouse model of Alzheimer's disease (Wang et al. 2014). 
Indeed, it would be interesting to investigate the effect of resveratrol oligomers found in the red grape skin 
polyphenolic extract, SGE (Baechler et al. 2014). Thus far, several resveratrol oligomers are known to 
inhibit cholinesterase (Table 1) and suppress ȕ-amyloid formation (Richard et al. 2011a), which might 
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therefore benefit Alzheimer's patients. For example, İ-viniferin glucoside (a resveratrol dimer), has been 
VKRZQWRUHGXFHȕ-amyloid aggregation and toxicity in vitro (Richard et al. 2011b). No formal assessment 
has been made in relation to changes in sphingolipid levels in neurons after treatment with resveratrol. 
Nevertheless, neuroprotection has been consistently observed at < 50µM of resveratrol, which is lower than 
the concentration required to inhibit SK1 activity (Ki=160 ± ȝ0 and to induce apoptosis (Capiralla et al. 
2012; Chen et al. 2005; Feng et al. 2013; Lim et al. 2012a; Marambaud et al. 2005; Wang et al. 2014). 
Therefore, low micromolar concentrations of resveratrol might mediate protection via a mechanism that 
does not involve changes in sphingolipid levels. A recent study has demonstrated that the resveratrol sulfate 
metabolites could effectively be taken up by cells and converted back to resveratrol in vivo (Patel et al. 
2013). Thus, caution is needed because resveratrol might be actively taken up by neurons, which could 
result in higher intracellular than plasma concentration. 
3.4 Metabolic disease  
Ceramide has been implicated in the pathogenesis of metabolic diseases; for instance, by promoting insulin 
resistance, lipotoxicity and cell death (Russo et al. 2013). Significant changes in sphingolipid levels and up-
regulation of ceramide-producing enzymes have been observed in obese rodents, which are accompanied 
by activation of pro-inflammatory cytokine signaling (Samad et al. 2006). Indeed, pro-inflammatory 
receptor TLR4-mediated signaling leads to the activation of NF-ț% and up-regulation of genes involved in 
the generation of ceramide and insulin resistance.  In addition, ceramide inhibits pro-survival Akt signaling 
to induce cell death and suppress insulin sensitivity (Holland et al. 2011a; Maceyka et al. 2012). By 
contrast, pro-survival S1P stimulated by adiponectin (a hormone with anti-inflammatory function) activates 
AMPK (in a S1P receptor-dependent manner), which is required for mitochondrial biogenesis (Holland et 
al. 2011b; Maceyka et al. 2012). Therefore, reducing the ceramide/S1P ratio is an attractive therapeutic 
goal for the management of diabetes.  
Resveratrol has been shown to improve insulin sensitivity and protect against metabolic disease in mice fed 
with high-fat diet.  This is associated with activation of AMPK/SIRT1/PGC-ĮSDWKZD\ (Baur et al. 2006). 
Moreover, resveratrol might exhibit anti-obesity action by reducing the body weight and abdominal fat of 
experimental mice (Baek et al. 2014). However, translation of these beneficial effects to the clinic has been 
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difficult. For example, there is a lack of physiological responses and no gene expression changes of 
metabolic and inflammatory biomarkers in obese man taking a high dose of resveratrol. Indeed, a recent 
review on all available clinical trials or interventions of obesity and Type II diabetes has found no 
significant benefits associated with resveratrol consumption (Timmers et al. 2013). Of note, clinical trials 
measuring health benefits might be difficult to design, which requires careful selection of patients, 
considering their health status, underlying morbidity, age, gender and sex. In addition, improved health and 
lifespan extension has been observed only in mice having high-fat diet but not in lean mice, suggesting that 
resveratrol might have a beneficial effect on patients with severe metabolic derangement. More controlled 
clinical studies are needed to investigate the therapeutic potential of resveratrol in metabolic diseases and 
its effects on sphingolipid metabolism. 
4. Summary and future direction 
The role of sphingolipids in the pathogenesis of human disease is widely recognized. During the past few 
years, more information regarding the therapeutic potential of resveratrol has also accumulated. 
Importantly, resveratrol can oligomerize into larger molecules with better potency than resveratrol and in 
some cases, better selectivity. More work is needed to investigate the in vivo activity of resveratrol 
oligomers and to assess their therapeutic efficacy and toxicity.  We consider that changes in sphingolipid 
metabolism in response to resveratrol and related oligomers are likely to be beneficial in the treatment of 
cancer patients and, more speculatively, in cardiovascular disease patients.  However, changes in 
sphingolipid metabolism in response to resveratrol in metabolic disorders and neurodegenerative diseases 
are contraindicated and likely deleterious.  This conclusion is based on findings that the effects of 
resveratrol on sphingolipid metabolism and disease progression are concentration-dependent. At low 
micromolar concentrations of resveratrol, which exhibit cardioprotective and neuroprotective properties, 
there is minimal perturbation of sphingolipid metabolism (excluding cellular uptake and increased local 
concentration). However, at high concentration (> 50µM), resveratrol increases pro-apoptotic ceramide and 
reduces pro-survival S1P levels, which suppresses cell growth and induces apoptosis. Therefore, a better 
understanding of the long-term effects of resveratrol (and its oligomers) on S1P- and ceramide-dependent 
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modulation of disease progression is required.  Nevertheless, the potential of the resveratrol/sphingolipid 
partnership might offer new avenues for the treatment of cancer. 
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